GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Simulations Plus Inc (NAS:SLP) » Definitions » ROE %

Simulations Plus (Simulations Plus) ROE %

: 9.23% (As of Feb. 2024)
View and export this data going back to 1997. Start your Free Trial

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Simulations Plus's annualized net income for the quarter that ended in Feb. 2024 was $16.12 Mil. Simulations Plus's average Total Stockholders Equity over the quarter that ended in Feb. 2024 was $174.69 Mil. Therefore, Simulations Plus's annualized ROE % for the quarter that ended in Feb. 2024 was 9.23%.

The historical rank and industry rank for Simulations Plus's ROE % or its related term are showing as below:

SLP' s ROE % Range Over the Past 10 Years
Min: 5.72   Med: 21.19   Max: 30.96
Current: 6.16

During the past 13 years, Simulations Plus's highest ROE % was 30.96%. The lowest was 5.72%. And the median was 21.19%.

SLP's ROE % is ranked better than
53.95% of 608 companies
in the Healthcare Providers & Services industry
Industry Median: 4.115 vs SLP: 6.16

Simulations Plus ROE % Historical Data

The historical data trend for Simulations Plus's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simulations Plus Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.66 9.63 6.08 7.26 5.72

Simulations Plus Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.69 9.60 1.26 4.54 9.23

Competitive Comparison

For the Health Information Services subindustry, Simulations Plus's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simulations Plus ROE % Distribution

For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's ROE % distribution charts can be found below:

* The bar in red indicates where Simulations Plus's ROE % falls into.



Simulations Plus ROE % Calculation

Simulations Plus's annualized ROE % for the fiscal year that ended in Aug. 2023 is calculated as

ROE %=Net Income (A: Aug. 2023 )/( (Total Stockholders Equity (A: Aug. 2022 )+Total Stockholders Equity (A: Aug. 2023 ))/ count )
=9.961/( (178.248+170.029)/ 2 )
=9.961/174.1385
=5.72 %

Simulations Plus's annualized ROE % for the quarter that ended in Feb. 2024 is calculated as

ROE %=Net Income (Q: Feb. 2024 )/( (Total Stockholders Equity (Q: Nov. 2023 )+Total Stockholders Equity (Q: Feb. 2024 ))/ count )
=16.116/( (172.341+177.038)/ 2 )
=16.116/174.6895
=9.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Feb. 2024) net income data. ROE % is displayed in the 30-year financial page.


Simulations Plus  (NAS:SLP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=16.116/174.6895
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(16.116 / 73.22)*(73.22 / 189.8755)*(189.8755 / 174.6895)
=Net Margin %*Asset Turnover*Equity Multiplier
=22.01 %*0.3856*1.0869
=ROA %*Equity Multiplier
=8.49 %*1.0869
=9.23 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Feb. 2024 )
=Net Income/Total Stockholders Equity
=16.116/174.6895
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (16.116 / 21.008) * (21.008 / 17.768) * (17.768 / 73.22) * (73.22 / 189.8755) * (189.8755 / 174.6895)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.7671 * 1.1824 * 24.27 % * 0.3856 * 1.0869
=9.23 %

Note: The net income data used here is four times the quarterly (Feb. 2024) net income data. The Revenue data used here is four times the quarterly (Feb. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Simulations Plus ROE % Related Terms

Thank you for viewing the detailed overview of Simulations Plus's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Simulations Plus (Simulations Plus) Business Description

Traded in Other Exchanges
N/A
Address
42505 Tenth Street West, Lancaster, CA, USA, 93534-7059
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. It generates maximum revenue from the software segment.
Executives
John Kenneth Paglia director 746 GRABLE PLACE, NEWBURY PARK CA 91320
Walter S Woltosz director, 10 percent owner, officer: Chairman and CEO 42505 10TH ST. WEST, LANCASTER CA 93534
Dibella John Anthony Ii officer: Division President 42505 10TH STREET WEST, LANCASTER CA 93534
Lisa Lavange director 42505 10TH ST., WEST, LANCASTER CA 93534
Steven Chang officer: President, Immunetrics 42505 10TH STREET WEST, LANCASTER CA 15203
Shawn Oconnor officer: Chief Executive Officer 42505 10TH STREET WEST, LANCASTER CA 93534-7059
Jill Fiedler-kelly officer: President, Cognigen Division 42505 10TH STREET WEST, LANCASTER CA 93534
Brett Howell officer: President, DILIsym Division 42505 10TH STREET WEST, LANCASTER CA 93534
William W Frederick officer: CFO C/O SIMULATIONS PLUS, INC., 42505 10TH STREET WEST, LANCASTER CA 93534
Daniel L Weiner director 800 WEST EL CAMINO REAL, SUITE 200, MOUNTAIN VIEW CA 94040
Sharlene Evans director 42505 10TH STREET WEST, LANCASTER CA 93534
Nguyen Nguyen officer: VP of Human Resources 42505 TENTH STREET WEST, LANCASTER CA 93534
David L. Ralph director 42505 10TH STREET WEST, LANCASTER CA 93534
John Robert Kneisel officer: CFO 42505 10TH STREET WEST, LANCASTER CA 93534
Grasela Thaddeus Henry Jr director, officer: President 1780 WEHRLE DRIVE SUITE 110, BUFFALO NY 14221